-+ 0.00%
-+ 0.00%
-+ 0.00%
Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery
Share
Listen to the news
Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery
  • Insilico Medicine Cayman TopCo's wholly owned subsidiary, Insilico Medicine Ltd., entered a strategic drug-discovery collaboration with Luoxin Pharmaceuticals.
  • The partnership will prioritize AI-powered research into digestive, metabolic and other non-oncology chronic diseases.
  • Specific projects remain subject to negotiation and definitive agreements, with implementation planned in phases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261113-12411853), on November 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending